Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shenzhen - Delayed Quote CNY

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)

Compare
58.11
-0.09
(-0.15%)
At close: March 28 at 3:04:16 PM GMT+8
Loading Chart for 300832.SZ
  • Previous Close 58.20
  • Open 59.90
  • Bid 58.13 x --
  • Ask 58.17 x --
  • Day's Range 57.80 - 58.64
  • 52 Week Range 57.25 - 97.20
  • Volume 4,324,114
  • Avg. Volume 3,480,130
  • Market Cap (intraday) 45.658B
  • Beta (5Y Monthly) -0.42
  • PE Ratio (TTM) 24.73
  • EPS (TTM) 2.35
  • Earnings Date --
  • Forward Dividend & Yield 1.00 (1.72%)
  • Ex-Dividend Date May 15, 2024
  • 1y Target Est 84.07

Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.

www.snibe.com

2,627

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300832.SZ

View More

Performance Overview: 300832.SZ

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300832.SZ
17.98%
SSE Composite Index (000001.SS)
0.01%

1-Year Return

300832.SZ
12.51%
SSE Composite Index (000001.SS)
11.31%

3-Year Return

300832.SZ
78.04%
SSE Composite Index (000001.SS)
4.26%

5-Year Return

300832.SZ
193.10%
SSE Composite Index (000001.SS)
20.89%

Compare To: 300832.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300832.SZ

View More

Valuation Measures

As of 3/28/2025
  • Market Cap

    45.66B

  • Enterprise Value

    43.08B

  • Trailing P/E

    24.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.29

  • Price/Book (mrq)

    5.62

  • Enterprise Value/Revenue

    9.71

  • Enterprise Value/EBITDA

    20.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    41.72%

  • Return on Assets (ttm)

    14.87%

  • Return on Equity (ttm)

    24.32%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    1.85B

  • Diluted EPS (ttm)

    2.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.59B

  • Total Debt/Equity (mrq)

    0.06%

  • Levered Free Cash Flow (ttm)

    967.3M

Research Analysis: 300832.SZ

View More

People Also Watch